Home » Stocks » AGLE

Aeglea Biotherapeutics, Inc. (AGLE)

Stock Price: $7.56 USD 0.22 (3.00%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 364.74M
Revenue (ttm) n/a
Net Income (ttm) -80.38M
Shares Out 49.02M
EPS (ttm) -1.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $7.56
Previous Close $7.34
Change ($) 0.22
Change (%) 3.00%
Day's Open 7.40
Day's Range 7.40 - 7.72
Day's Volume 89,980
52-Week Range 6.43 - 11.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

AUSTIN, Texas, May 10, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...

4 days ago - PRNewsWire

AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people w...

1 week ago - PRNewsWire

AUSTIN, Texas, May 3, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...

1 week ago - PRNewsWire

AUSTIN, Texas, April 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people...

1 month ago - PRNewsWire

AUSTIN, Texas and STOCKHOLM, March 22, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...

1 month ago - PRNewsWire

AUSTIN, Texas, March 18, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

1 month ago - PRNewsWire

AUSTIN, Texas, Feb. 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

2 months ago - PRNewsWire

AUSTIN, Texas, Feb. 3, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...

3 months ago - PRNewsWire

AUSTIN, Texas, Jan. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people ...

4 months ago - PRNewsWire

Aeglea (AGLE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

4 months ago - Zacks Investment Research

AUSTIN, Texas, Dec. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...

4 months ago - PRNewsWire

AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...

5 months ago - PRNewsWire

AUSTIN, Texas, Nov. 24, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...

5 months ago - PRNewsWire

AUSTIN, Texas, Nov. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

5 months ago - PRNewsWire

Aeglea (AGLE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

6 months ago - Zacks Investment Research

Billionaire investor Steven Cohen (Trades, Portfolio) revealed a new stake in Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) late last week.

6 months ago - GuruFocus

AUSTIN, Texas, Oct. 26, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

6 months ago - PRNewsWire

AUSTIN, Texas, Oct. 5, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...

7 months ago - PRNewsWire

AUSTIN, Texas, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovat...

8 months ago - GlobeNewsWire

Aeglea (AGLE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

AUSTIN, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovati...

8 months ago - GlobeNewsWire

Does Aeglea Biotherapeutics (AGLE) have what it takes to be a top stock pick for momentum investors? Let's find out.

10 months ago - Zacks Investment Research

Is (AGLE) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify several Top Shor...

Other stocks mentioned: DVAX, LQDA, PHAS, SEEL
10 months ago - Forbes

Aeglea BioTherapeutics (AGLE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

11 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics

11 months ago - Zacks Investment Research

AUSTIN, Tx., May 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative ...

11 months ago - GlobeNewsWire

  Pegzilarginase Showed Durable Clinical Response at 56 Week Analysis

11 months ago - GlobeNewsWire

Is (AGLE) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

Find Strong Stocks During the Coronavirus with New Analyst Coverage

Other stocks mentioned: SQNS, VRSN
11 months ago - Zacks Investment Research

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: NJR, SQNS, VRSN
11 months ago - Zacks Investment Research

Aeglea BioTherapeutics (AGLE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Aeglea BioTherapeutics, Inc. (AGLE).

1 year ago - Zacks Investment Research

Aeglea (AGLE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

AUSTIN, Texas, April 30, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions f...

1 year ago - GlobeNewsWire

AUSTIN, Texas, April 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive ...

1 year ago - GlobeNewsWire

AUSTIN, Texas, April 27, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive...

1 year ago - GlobeNewsWire

AUSTIN, Texas, April 08, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions f...

1 year ago - GlobeNewsWire

AUSTIN, Texas, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions fo...

1 year ago - GlobeNewsWire

Live Webcast Scheduled for 5:30 p.m. ET on Monday, September 9 Live Webcast Scheduled for 5:30 p.m. ET on Monday, September 9

1 year ago - GlobeNewsWire

Sustained Control of Plasma Arginine Accompanied by Clinical Response; Overall Clinical Responder Rate of 79%

1 year ago - GlobeNewsWire

Management to Host Conference Call at 9:00 a.m. ET on Tuesday, September 3 Management to Host Conference Call at 9:00 a.m. ET on Tuesday, September 3

1 year ago - GlobeNewsWire

The stock has gained 15% during the past month due to insider buying.

1 year ago - Seeking Alpha

President & CEO of Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Anthony G. Quinn bought 31,905 shares of AGLE on 06/14/2019 at an average price of $6.16 a share.

1 year ago - GuruFocus

Aeglea reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.

2 years ago - Zacks Investment Research

About AGLE

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeli... [Read more...]

Industry
Biotechnology
IPO Date
Apr 7, 2016
Stock Exchange
NASDAQ
Ticker Symbol
AGLE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for AGLE stock is "Buy." The 12-month stock price forecast is 15.86, which is an increase of 109.79% from the latest price.

Price Target
$15.86
(109.79% upside)
Analyst Consensus: Buy